Does the media refer more to CORT or GPCR?

In the previous week, Corcept Therapeutics had 20 more articles in the media than Structure Therapeutics. MarketBeat recorded 24 mentions for Corcept Therapeutics and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.40 beat Corcept Therapeutics' score of 0.95 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 17 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or GPCR?

In the previous week, Elanco Animal Health had 10 more articles in the media than Structure Therapeutics. MarketBeat recorded 14 mentions for Elanco Animal Health and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.40 beat Elanco Animal Health's score of 1.29 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or GPCR?

In the previous week, Axsome Therapeutics had 28 more articles in the media than Structure Therapeutics. MarketBeat recorded 32 mentions for Axsome Therapeutics and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.40 beat Axsome Therapeutics' score of 0.84 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RDY or GPCR?

Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 134.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 3 Strong Buy rating(s) 2.89

Does the media prefer RDY or GPCR?

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 4 articles in the media. Structure Therapeutics' average media sentiment score of 1.40 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Structure Therapeutics (GPCR) Competitors

$47.37 -1.85 (-3.76%)

As of 08/28/2026 04:00 PM Eastern

Compare

GPCR vs. CORT, ELAN, AXSM, RDY, and CRNX

Should you buy Structure Therapeutics stock or one of its competitors? Structure Therapeutics's main competitors and comparable companies include Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Structure Therapeutics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Corcept Therapeutics has a net margin of 6.52% compared to Structure Therapeutics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Structure Therapeutics	N/A	-25.56%	-24.31%

Corcept Therapeutics currently has a consensus target price of $138.17, suggesting a potential upside of 21.33%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 134.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Corcept Therapeutics had 20 more articles in the media than Structure Therapeutics. MarketBeat recorded 24 mentions for Corcept Therapeutics and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.40 beat Corcept Therapeutics' score of 0.95 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	17 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, suggesting that its stock price is 243% less volatile than the broader market.

Corcept Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.17	$99.65M	$0.42	271.14
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Summary

Corcept Therapeutics beats Structure Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Elanco Animal Health has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, suggesting that its share price is 243% less volatile than the broader market.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Elanco Animal Health had 10 more articles in the media than Structure Therapeutics. MarketBeat recorded 14 mentions for Elanco Animal Health and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.40 beat Elanco Animal Health's score of 1.29 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$5.02B	2.40	-$232M	-$0.41	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Elanco Animal Health currently has a consensus price target of $29.09, indicating a potential upside of 20.41%. Structure Therapeutics has a consensus price target of $110.91, indicating a potential upside of 134.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Structure Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Structure Therapeutics	N/A	-25.56%	-24.31%

Summary

Structure Therapeutics beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Axsome Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 28 more articles in the media than Structure Therapeutics. MarketBeat recorded 32 mentions for Axsome Therapeutics and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.40 beat Axsome Therapeutics' score of 0.84 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics presently has a consensus price target of $267.60, indicating a potential upside of 34.46%. Structure Therapeutics has a consensus price target of $110.91, indicating a potential upside of 134.13%. Given Structure Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Structure Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	13.42	-$183.17M	-$3.75	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Structure Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. Structure Therapeutics' return on equity of -25.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Structure Therapeutics	N/A	-25.56%	-24.31%

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Structure Therapeutics beats Axsome Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 134.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 4 articles in the media. Structure Therapeutics' average media sentiment score of 1.40 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.84	$456M	$0.44	27.66
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Structure Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Structure Therapeutics	N/A	-25.56%	-24.31%

Summary

Dr. Reddy's Laboratories beats Structure Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Structure Therapeutics (NASDAQ:GPCR) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Structure Therapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Crinetics Pharmaceuticals	$42.16M	213.46	-$465.32M	-$5.04	N/A

In the previous week, Crinetics Pharmaceuticals had 6 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 4 mentions for Structure Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Structure Therapeutics' score of 1.40 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Structure Therapeutics presently has a consensus price target of $110.91, indicating a potential upside of 134.13%. Crinetics Pharmaceuticals has a consensus price target of $81.00, indicating a potential downside of 4.53%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Structure Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Structure Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Structure Therapeutics' return on equity of -25.56% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Structure Therapeutics has a beta of -1.43, indicating that its share price is 243% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

Summary

Structure Therapeutics beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GPCR vs. The Competition

Export

Metric	Structure Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.30B	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-47.37	787.65	273.16	25.45
Price / Sales	N/A	793.10	605.06	76.64
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	2.44	11.97	12.98	6.14
Net Income	-$141.20M	$2.83B	$3.48B	$348.86M
7 Day Performance	-3.50%	0.39%	0.13%	-0.80%
1 Month Performance	-4.24%	5.34%	7.08%	4.13%
1 Year Performance	145.44%	6.05%	24.67%	15.17%

Structure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GPCR Structure Therapeutics	2.2139 of 5 stars	$47.37 -3.8%	$110.91 +134.1%	+145.4%	$3.30B	N/A	N/A	136	Positive News
CORT Corcept Therapeutics	4.0811 of 5 stars	$118.27 +0.9%	$138.17 +16.8%	+63.3%	$12.64B	$761.41M	278.43	300	News Coverage Insider Trade
ELAN Elanco Animal Health	4.6926 of 5 stars	$23.55 -0.3%	$29.09 +23.5%	+31.5%	$11.77B	$5.02B	N/A	9,400	Positive News
AXSM Axsome Therapeutics	4.2322 of 5 stars	$217.02 +0.3%	$267.60 +23.3%	+64.1%	$11.18B	$776.57M	N/A	380	News Coverage Analyst Revision
RDY Dr. Reddy's Laboratories	1.7739 of 5 stars	$12.07 -0.3%	N/A	-14.3%	$10.11B	$3.58B	27.52	27,527	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GPCR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Competitors

GPCR vs. CORT, ELAN, AXSM, RDY, and CRNX

How does Structure Therapeutics compare to Corcept Therapeutics?

Summary

How does Structure Therapeutics compare to Elanco Animal Health?

Summary

How does Structure Therapeutics compare to Axsome Therapeutics?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Structure Therapeutics (GPCR) Competitors

GPCR vs. CORT, ELAN, AXSM, RDY, and CRNX

How does Structure Therapeutics compare to Corcept Therapeutics?

Is CORT or GPCR more profitable?

Do analysts recommend CORT or GPCR?

Do institutionals & insiders hold more shares of CORT or GPCR?

Does the media refer more to CORT or GPCR?

Which has more risk and volatility, CORT or GPCR?

Which has stronger valuation and earnings, CORT or GPCR?

Summary

How does Structure Therapeutics compare to Elanco Animal Health?

Which has more risk & volatility, ELAN or GPCR?

Do insiders and institutionals have more ownership in ELAN or GPCR?

Does the media prefer ELAN or GPCR?

Which has better valuation and earnings, ELAN or GPCR?

Do analysts recommend ELAN or GPCR?

Is ELAN or GPCR more profitable?

Summary

How does Structure Therapeutics compare to Axsome Therapeutics?

Which has more risk & volatility, AXSM or GPCR?

Does the media refer more to AXSM or GPCR?

Do analysts rate AXSM or GPCR?

Which has higher valuation & earnings, AXSM or GPCR?

Is AXSM or GPCR more profitable?

Do institutionals & insiders believe in AXSM or GPCR?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Do analysts rate RDY or GPCR?

Does the media prefer RDY or GPCR?

Do insiders and institutionals hold more shares of RDY or GPCR?

Which has more risk and volatility, RDY or GPCR?

Which has preferable valuation & earnings, RDY or GPCR?

Is RDY or GPCR more profitable?

Summary

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Which has preferable valuation & earnings, GPCR or CRNX?

Does the media refer more to GPCR or CRNX?

Do analysts recommend GPCR or CRNX?

Is GPCR or CRNX more profitable?

Do institutionals & insiders believe in GPCR or CRNX?

Which has more volatility & risk, GPCR or CRNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools